Dr. Reddy’s Laboratories Ltd ADR Asset Resilience Ratio
Dr. Reddy’s Laboratories Ltd ADR asset resilience ratio. Dr. Reddy’s Laboratories Ltd ADR (RDY) has an Asset Resilience Ratio of 11.36% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dr. Reddy’s Laboratories Ltd ADR (RDY) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
Asset resilience ratio of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. This chart shows how Dr. Reddy’s Laboratories Ltd ADR's Asset Resilience Ratio has changed over time. See Dr. Reddy’s Laboratories Ltd ADR (RDY) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Dr. Reddy’s Laboratories Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RDY current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.93 Billion | 11.36% |
| Total Liquid Assets | $63.93 Billion | 11.36% |
Asset Resilience Insights
- Moderate Liquidity: Dr. Reddy’s Laboratories Ltd ADR has 11.36% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Dr. Reddy’s Laboratories Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Dr. Reddy’s Laboratories Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Dr. Reddy’s Laboratories Ltd ADR Asset Resilience Ratio by Year (2000–2025)
Dr. Reddy’s Laboratories Ltd ADR asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Dr. Reddy’s Laboratories Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 9.28% | $45.76 Billion | $492.99 Billion | -10.58pp |
| 2024-03-31 | 19.86% | $76.96 Billion | $387.52 Billion | +1.55pp |
| 2023-03-31 | 18.31% | $58.95 Billion | $321.85 Billion | +8.21pp |
| 2022-03-31 | 10.10% | $29.59 Billion | $292.83 Billion | -6.03pp |
| 2021-03-31 | 16.14% | $586.04 Million | $3.63 Billion | +2.10pp |
| 2020-03-31 | 14.04% | $431.11 Million | $3.07 Billion | +4.00pp |
| 2019-03-31 | 10.04% | $22.64 Billion | $225.43 Billion | +1.47pp |
| 2018-03-31 | 8.57% | $19.34 Billion | $225.60 Billion | +0.92pp |
| 2017-03-31 | 7.65% | $16.82 Billion | $219.82 Billion | -9.22pp |
| 2016-03-31 | 16.87% | $35.03 Billion | $207.65 Billion | -0.72pp |
| 2015-03-31 | 17.59% | $34.26 Billion | $194.76 Billion | +2.85pp |
| 2014-03-31 | 14.74% | $25.08 Billion | $170.22 Billion | +2.82pp |
| 2013-03-31 | 11.91% | $169.63 Billion | $1.42 Trillion | +2.90pp |
| 2012-03-31 | 9.02% | $10.77 Billion | $119.48 Billion | +8.98pp |
| 2011-03-31 | 0.03% | $33.00 Million | $95.00 Billion | -5.16pp |
| 2010-03-31 | 5.19% | $4.17 Billion | $80.33 Billion | +4.56pp |
| 2009-03-31 | 0.63% | $530.00 Million | $83.79 Billion | -4.93pp |
| 2008-03-31 | 5.56% | $4.75 Billion | $85.45 Billion | +5.55pp |
| 2007-03-31 | 0.02% | $15.38 Million | $86.12 Billion | 0.00pp |
| 2006-03-31 | 0.02% | $14.70 Million | $68.77 Billion | -1.04pp |
| 2005-03-31 | 1.06% | $310.87 Million | $29.29 Billion | -8.47pp |
| 2004-03-31 | 9.53% | $2.54 Billion | $26.68 Billion | -28.32pp |
| 2003-03-31 | 37.85% | $8.71 Billion | $23.03 Billion | +37.85pp |
| 2002-03-31 | 0.00% | $516.00K | $18.95 Billion | 0.00pp |
| 2001-03-31 | 0.00% | $399.00K | $11.84 Billion | -2.47pp |
| 2000-03-31 | 2.47% | $3.84 Million | $155.57 Million | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more